Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials

  • Raymond J. Playford,
  • Meg Cattell,
  • Tania Marchbank

Correction: Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials

  • Raymond J. Playford, 
  • Meg Cattell, 
  • Tania Marchbank
PLOS
x
  • Article
  • Metrics
  • Comments
  • Media Coverage

In Table 1, there are errors in the titles of the products tested under “COLOSTRUM”, the values under “Total stated protein (g/100 g)” and “Total IgG (g/100g)”, and the “Lot number” values. Please see the correct Table 1 here.

thumbnail
Table 1. Commercial colostrum sample information provided by producer.

https://doi.org/10.1371/journal.pone.0240392.t001

Table shows source of colostrum samples and product data sheet information for total protein, total IgG, lot numbers and recommended storage conditions, NS = not stated. RT = (store at) room temperature. Storage advice was either present on data sheet or through direct contact with producer. NB list of products are described in random order and do not relate to the order of bioactivity.

Some of the symbols in the caption for Fig 4 are incorrect. Please see the complete, correct Fig 4 caption here. The publisher apologizes for the errors.

thumbnail
Fig 4. Change in colostral biological and immunoactivity post calving using AGS cells.

Colostrum was collected at first and second milking and daily for the following 3 days from 6 cows post calving. Samples were then analysed for pro-proliferative activity (AGS cells) using Alamar Blue and growth factor concentrations using commercial ELISA kits. A. Proliferative results comparing samples using 1 mg powder/ml. B. Proliferative results comparing samples standardised so that each well received 0.4 mg protein/ml. Results expressed as % response compared to effect caused by adding 1μg/ml EGF (positive control, defined as 100%). SFM shows result of serum free medium alone. Results expressed as mean +/- SEM of 6 animals per time point, with each sample measured in quadruplicate. C. Change in total protein concentration in the dried colostrum samples over the four-day period. D. Growth factor immunoreactivity expressed as % of Day 0–1 sample (absolute values of day 0–1 given in main text); EGF (▲), TGFβ (▼), bovine haptoglobin (●), bovine betacellulin (■), IGF-1 (□) and IgG (○). Results expressed as mean +/- SEM of 6 animals per time point, with each sample measured in triplicate. For A-D, ** signifies p<0.01 vs Day 0–1 value.

https://doi.org/10.1371/journal.pone.0240392.g001

Reference

  1. 1. Playford RJ, Cattell M, Marchbank T (2020) Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials. PLoS ONE 15(6): e0234719. https://doi.org/10.1371/journal.pone.0234719 pmid:32555629